Clinical Trials Browser

Adrenal Cortex Neoplasms, Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms, Unknown Primary, Paraganglioma, Penile Neoplasms, Pheochromocytoma, Carcinoma, Small Cell, Vascular Neoplasms

NCT05036434 2026-01-23

ACCOMPLISH

Phase 2 Active not recruiting

30 enrolled

Endocrine

Adrenocortical Carcinoma

NCT06232564 2026-01-14

PELICAN

Phase 2 Active not recruiting

20 enrolled

EndocrineNET

Neuroendocrine Tumors

NCT02628067 2025-09-22

KEYNOTE 158

Phase 2 Active not recruiting

1,609 enrolled 9 FDA

EndocrineGastrointestinalGynecologicHead & NeckNETOther solid neoplasmThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Anus Neoplasms, Bile Duct Neoplasms, Biliary Tract Neoplasms, Carcinoid Tumor, Uterine Cervical Neoplasms, Mesothelioma, Parotid Neoplasms, Salivary Gland Neoplasms, Thyroid Neoplasms, Vulvar Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Neuroendocrine Tumors, Microsatellite Instability, Small Cell Lung Carcinoma

NCT03647163 2025-09-16

Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors

Phase 1/2 Active not recruiting

33 enrolled

EndocrineGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Neuroendocrine

NCT03457948 2025-09-03

Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases

Phase 2 Active not recruiting

32 enrolled

EndocrineNET

Neuroendocrine Tumors

Clinical Trials

Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma

Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer

Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer

PLANE-PC

Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic

ACCOMPLISH

PELICAN

KEYNOTE 158

Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors

Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases